N2OFF, Inc. (NITO)
NASDAQ: NITO · Real-Time Price · USD
2.614
-0.046 (-1.75%)
Nov 20, 2025, 2:05 PM EST - Market open
N2OFF Revenue
N2OFF had revenue of $2.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $209.00K, up 19.85% year-over-year. In the year 2024, N2OFF had annual revenue of $210.00K, down -20.15%.
Revenue (ttm)
$209.00K
Revenue Growth
+19.85%
P/S Ratio
7.34
Revenue / Employee
$41,800
Employees
5
Market Cap
7.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.00K | -53.00K | -20.15% |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rio Tinto Group | 53.73B |
| BHP Group | 51.26B |
| CRH plc | 36.90B |
| Linde | 33.50B |
| Freeport-McMoRan | 26.00B |
| The Sherwin-Williams Company | 23.28B |
| Newmont | 21.50B |
| Ecolab | 15.89B |
NITO News
- 2 days ago - N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination - GlobeNewsWire
- 21 days ago - N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers - GlobeNewsWire
- 4 weeks ago - N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 7 weeks ago - N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe - GlobeNewsWire
- 2 months ago - N2OFF to Expand its Melz Solar Project with Battery Storage - GlobeNewsWire
- 4 months ago - N2OFF Completes $1.2 million of its $2.7 million Total Commitment to Finance 196MWp Battery Energy Storage Assets in Italy - GlobeNewsWire
- 5 months ago - N2OFF is Increasing its Investment in Melz Project to Explore Additional 40-60 MW Battery Storage - GlobeNewsWire